[Polarizing therapy in intraventricular and atrio-ventricular conduction disorders].
D000219:Adams-Stokes Syndrome / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001919:Bradycardia / Q000188:drug therapy; D002037:Bundle-Branch Block / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D005260:Female; D005947:Glucose / Q000008:administration & dosage*; D006327:Heart Block / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D009921:Metaproterenol / Q000008:administration & dosage; D008875:Middle Aged; D011189:Potassium Chloride / Q000008:administration & dosage*; D012118:Resorcinols / Q000008:administration & dosage*
D007328:Insulin; D012118:Resorcinols; D009921:Metaproterenol; D011189:Potassium Chloride; D005947:Glucose
La terapia polarizzante nei disturbi di conduzione intraventricolari ed atrio-ventricolari.